Skip to main content

Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.

Publication ,  Journal Article
Weinfurt, KP; Castel, LD; Li, Y; Timbie, JW; Glendenning, GA; Schulman, KA
Published in: Med Care
February 2004

BACKGROUND: Research on individual differences in health-related quality of life (HRQOL) can identify intervention targets and important covariates in analyses of treatment outcomes. OBJECTIVES: The objectives of this study were to describe HRQOL trajectories for women with metastatic breast cancer in a randomized trial of bisphosphonates and to identify characteristics associated with variations in HRQOL. RESEARCH DESIGN: We conducted a prospective quality-of-life study within a randomized, controlled trial. SUBJECTS: We studied women with metastatic breast cancer receiving zoledronic acid or pamidronate disodium to reduce the incidence of skeletal-related events (SREs). MAIN OUTCOME MEASURES: HRQOL was measured at fixed time points during the trial. Individual growth-curve modeling was used to describe longitudinal trajectories and to identify predictors of trajectories. RESULTS: For most domains of HRQOL, the mean trajectory reflected a mild increase, which leveled off later in the trial. Older age and full-time employment were associated with higher baseline HRQOL. Longer time from cancer diagnosis to randomization, lower Eastern Cooperative Oncology Group (ECOG) status (score of 2 ["inactive"]), and a history of SREs were associated with lower baseline HRQOL. Significant differences across geographic regions were observed for all domains. Active ECOG status (score of 0-1) at baseline was predictive of greater increases in all domains of HRQOL except Social/Family Well-Being. Age, geographic region, and time from first bone metastases to randomization were associated with longitudinal changes in some domains. CONCLUSIONS: Women with metastatic breast cancer receiving bisphosphonates for prevention of SREs experienced an overall increase in HRQOL. Variations among women's experiences are explained partly by such characteristics as a history of SREs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Med Care

DOI

ISSN

0025-7079

Publication Date

February 2004

Volume

42

Issue

2

Start / End Page

164 / 175

Location

United States

Related Subject Headings

  • Zoledronic Acid
  • United States
  • Quality of Life
  • Prospective Studies
  • Pamidronate
  • Outcome and Process Assessment, Health Care
  • Middle Aged
  • Imidazoles
  • Humans
  • Health Policy & Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weinfurt, K. P., Castel, L. D., Li, Y., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2004). Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care, 42(2), 164–175. https://doi.org/10.1097/01.mlr.0000108746.69256.45
Weinfurt, Kevin P., Liana D. Castel, Yun Li, Justin W. Timbie, G Alastair Glendenning, and Kevin A. Schulman. “Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.Med Care 42, no. 2 (February 2004): 164–75. https://doi.org/10.1097/01.mlr.0000108746.69256.45.
Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004 Feb;42(2):164–75.
Weinfurt, Kevin P., et al. “Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.Med Care, vol. 42, no. 2, Feb. 2004, pp. 164–75. Pubmed, doi:10.1097/01.mlr.0000108746.69256.45.
Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004 Feb;42(2):164–175.

Published In

Med Care

DOI

ISSN

0025-7079

Publication Date

February 2004

Volume

42

Issue

2

Start / End Page

164 / 175

Location

United States

Related Subject Headings

  • Zoledronic Acid
  • United States
  • Quality of Life
  • Prospective Studies
  • Pamidronate
  • Outcome and Process Assessment, Health Care
  • Middle Aged
  • Imidazoles
  • Humans
  • Health Policy & Services